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Metastatic disease accounts for more than 90% 
of cancer deaths. For example, the life expec-
tancy of women who have breast cancer has 
dramatically improved over the past 10 years, 
but women with metastatic disease have a 5-year 
survival rate of only 20%. Approximately 30% of 
women without evidence of metastatic disease at 
the time of resection of the primary tumor have 
metastatic disease develop later. Some women 
with small tumors and no evidence of lymph-
node involvement have a recurrence 10 to 15 years 
after surgery. These and other observations sug-
gest that cells from primary tumors can seed 
distant sites early and that these cells can lie 
dormant for many years until they “reawaken,” 
whereupon they develop into metastatic and 
usually lethal tumors. Since metastatic disease is 
a key component of tumor-related morbidity and 
mortality, it is essential to develop new thera-
peutics directed at these latent metastatic cells 
or at micrometastases before they develop into 
difficult-to-treat large tumors.
Pathological analyses suggest that tumor cells 
can seed to and be maintained in many different 
organs. How do they escape immune attack and 
survive? How is their dormant state maintained, 
and what stimulates their escape from dormancy? 
A study reported by Malladi et al.1 begins to 
answer these questions. The investigators de-
rived, from a human metastatic lung-cancer cell 
line and a breast-cancer cell line, latency-compe-
tent cells that seed distant sites after experimen-
tal tail-vein inoculation into immunocompro-
mised mice but that remain largely dormant for 
several months. These cells form tumors when 
injected into orthotopic sites but do not grow in 
the metastatic context. Isolation of these latency-
competent cells from the lung indicated that 
they had properties of stem cells: they had robust 
expression of the transcription factors Sox9 and 
Sox2 (as do stem cells of mammary and lung 
adenocarcinomas, respectively) (Fig. 1). The au-
thors also found that latency-competent cells 
entered a slowly proliferating state that is regu-
lated by these Sox transcription factors. Despite 
the ability of these cells to survive for long periods 
at the sites of simulated metastasis, initial sur-
vival was very low, which suggested attrition by 
either mechanical or metabolic stress or through 
immune ablation.
Previous studies have shown that natural 
killer cells kill metastasizing cells, and Malladi 
et al. found that ablation of natural killer cells 
dramatically increased the ability of latency-
competent cells to survive and metastasize. The 
level of natural killer cell activity is determined 
by the extent to which “inhibitory” and “activat-
ing” receptors are stimulated by their ligands; 
Malladi et al. observed that latency-competent 
cells expressed high levels of the inhibitory li-
gands, and this elevated level of expression pro-
tected these cells against ex vivo natural killer 
cell killing assays. Gene profiling also revealed 
that certain signaling pathways were altered in 
latency-competent cells, including down-regula-
tion of Wnt signaling and high expression of the 
Wnt inhibitor, Dkk1. Knockdown of Dkk1 stimu-
lated the proliferation of latency-competent cells 
and, through up-regulation of activating ligands, 
increased their susceptibility to killing by natu-
ral killer cells. They found a dramatically in-
creased rate of metastatic tumor growth in mice 
that were depleted of natural killer cells, which 
suggested that a dip in or a waning of immunity 
is a contributory factor to the emergence of micro-
metastases from the latent state.
A major rate-limiting step for metastatic cells 
is at the stage of extravasation from the blood-
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stream into the target tissue (site of metastasis). 
Experimentally, natural killer cells represent a 
barrier to this process and are recruited by a 
subpopulation of patrolling nonclassical mono-
cytes to the extravasating tumor cells.2 The clas-
sical monocytes are also recruited to the site of 
invading tumor cells; these monocytes enhance 
tumor-cell extravasation and survival.3 The cur-
rent study suggests that latency-competent cells 
survive because of the Dkk1-mediated dialing 
down of immunogenicity and Sox-maintained 
“stemness”: both of these states are known to 
confer on the cell resistance to attack by natural 
killer cells. Latency-competent cells appear to 
stochastically undergo cycles of proliferation 
and loss, perhaps reflecting changing balances 
between the protumor and antitumor actions of 
the immune system.4 The results of the study by 
Malladi et al. need to be extended to less artifi-
cial models of metastatic latency, involving pro-
gressive heterogeneous spontaneously arising 
tumors in immune-competent mice. Neverthe-
less, their study points to the possibility that the 
eradication of latent metastatic cells might one 
Figure 1. When the Tumor Cell Sleeps No More.
Metastatic tumor cells escape from the circulation to become established at distant sites. Patrolling monocytes recruit natural killer 
(NK) cells to these extravasating cells, which kill them, thus reducing seeding efficiency. Countering this effect are the classical mono-
cytes, which are recruited to promote extravasation and survival of the cancer cells. A study recently reported by Malladi et al.1 showed 
that rare surviving cells can enter into a latent stem-cell–like state characterized by Sox2 or Sox9 expression and that these cells evade 
NK cells through Dkk1-mediated inhibition of Wnt signaling that down-regulates NK-cell–activating receptors. They proposed that the 
cells undergo cycles of proliferation and death until a secondary event allows them to respond to Wnt proteins — perhaps expressed by 
monocytes or macrophages — that may increase expression of NK-cell–inhibitory ligands, whereupon they grow into metastatic lethal 
lesions.
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day be achieved therapeutically, perhaps by en-
hancing Wnt signaling in micrometastases (one 
means of achieving this would be through block-
ing of DKK1 binding) and coincident transfer of 
activated tumor-targeted natural killer cells.5 
The danger of this approach is that Wnt ligands 
are protumoral and involved in metastasis. An 
alternative approach may be to find means of 
activating in the latency-competent cell expres-
sion of ligands that activate natural killer cells, 
making the latency-competent cells susceptible 
to attack.
Disclosure forms provided by the author are available at 
NEJM.org.
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